FOR IMMEDIATE RELEASE

TIGERLILY FOUNDATION CAPTURES SOCIAL DETERMINANTS OF HEALTH DATA, AND ELIMINATES BARRIERS THROUGH RAISE, TIGERLILY’S PATIENT-DRIVEN SUPPORT PLATFORM

ALDIE, Va. – September 01, 2023 – The Tigerlily Foundation (Tigerlily), a leading breast cancer patient advocacy organization, has launched a platform focused on solving the non-clinical barriers cancer patients face as they go through treatment and highlighting ways in which the social determinants of health (SDOH) data gathered through Tigerlily’s patient-facing platform, RAISE (Resources and Assistance to Support Empowerment), can be utilized to improve trial diversity, adherence, and accrual.

RAISE is a patient-created platform that addresses access and adherence to care and eliminates barriers and health equity challenges that cancer patients face. The RAISE platform breaks down barriers by enabling patients living with breast cancer to get support in several ways: 1) leveraging networks of friends, family, and anonymous donors to get the non-clinical support they need without the stigma associated with asking for help; 2) getting direct support from Tigerlily; and 3) getting support through strategic partnerships.

The data generated through RAISE helps identify potential risk factors for patients that might impact a patient’s ability to comply with, or adhere to, the treatment they are on. By identifying these issues, Tigerlily can work with non-profit and corporate partners to put services in place that will help mitigate these risks for patients.

“The best drugs, treatment plans, and technology will not make a difference if the patient struggles to focus on and adhere to treatment because they do not have the practical support they need. The RAISE platform allow us to see these “gaps in care” so that we can provide our patients with the right support at the right time. By doing this we believe we can address both Health Equity and Health Access. In addition, it is past time that we stop talking about the problem and putting in place solutions for patients. We are calling on sponsors and any company that has a health equity commitment to put their money where their mouth is and partner with us to ensure that patients NO LONGER face barriers to treatment and clinical trials. There are more than enough resources and funding to make this happen. While people have been talking about fixing barriers, there is not enough urgency in the doing, so we did it. Let us now work together to expand this resource, so that patients do not die simply because of a lack of support. No one should have to choose between having a roof over their head and feeding their family - or surviving cancer. We are thankful to our partners at Merck, Daiichi-Sankyo, Takeda, Seagen and Genentech for providing support that enabled us to make this platform and the resources it offers, possible,” Maimah Karmo, Founder and CEO of The Tigerlily Foundation.

“As an inaugural sponsor of Tigerlily Foundation’s RAISE program, Seagen is proud of our long-standing partnership and efforts with Tigerlily to support communities of color in gaining improved access to clinical trials. From collaborating to improve patient education and care navigation to supporting programs that provide critical peer support and advocacy, we are honored to continue our work with Tigerlily to make important strides in advancing health equity,” said Kristin Olson, Senior Director of Patient Advocacy at Seagen.

“We look forward to the potential impact RAISE will provide for breast cancer patients by supporting them through their healthcare journeys,” said Lauren Davis, Director of Patient Advocacy Relations at Genentech, a member of the Roche Group. “Genentech is deeply committed to addressing barriers and
reducing disparities in healthcare access and clinical research participation for historically underserved groups. By coming together, we aim to expand our efforts and, as a result, help more people.”

Identifying risk factors is especially helpful to clinical trial sponsors. Rather than guessing at patient needs, RAISE allows sponsors to understand, in real-time, to trial participants’ needs. Sponsors can utilize this information to better identify the needs of patients in specific geographies, within key demographics, or with subtypes of breast cancer – enabling them to create highly personalized risk mitigation plans. This will allow sponsors to proactively build appropriate support mechanisms into their study protocols and ensure that their trial sites can meet the needs of their patient populations. Using RAISE to help mitigate barriers and improve access opens doors for broader underrepresented populations, which in turn can help meet the diversity and equity requirements spelled out in the required trial Diversity Action Plans.

“Only by better realizing the risk factors, gaps in care and access for the underserved community will we be able to better support the unmet needs of people living with cancer and make their journey as frictionless as possible. Daiichi Sankyo is proud to support RAISE (Resources and Assistance to Support Empowerment), helping to address both health equity and health access so that clinical trial participants have the non-clinical support needed to help improve their outcomes,” said Gissoo DeCotiis, Global Head of Advocacy & Strategic Relations, Global Medical Affairs, Oncology at Daiichi Sankyo, Inc.

The RAISE platform allows sponsors two ways in which they can support their clinical trial participants. They can either provide support through the platform by giving directly to trial participants or by providing financial support through RAISE’s overarching fund, through which funds are apportioned to enrolled study participants. Embedding RAISE in a clinical trial budget up front is also a way to highlight a sponsor’s commitment to truly investing in diversity in clinical trials. This ensures trial participants have the support they need so they can comply with, and adhere to, the trial requirements.

“We are excited to play a key role in RAISE as Tigerlily’s technology partner. Often, underrepresented, and underserved patients struggle to comply with the trials they are on because they lack the non-clinical support they need. By white-labeling our WiTT Support Registry to Tigerlily, RAISE will help improve outcomes by shedding light on the key non-clinical needs of patients and provide Sponsors with the necessary visibility into the challenges their trial participants face so that they can increase compliance and adherence for their trial,” said Rahul Mahadevan, Founder and CEO of The WiTT Group.

The RAISE platform is free for patients and donors to utilize. Patients can start getting the help they need by registering at http://tigerlily.wittforever.com, creating a “support registry” of needs (both financial and non-financial), and inviting their personal community to join their care circle to help them. Tigerlily will continue to work with The WiTT Group to continue to expand the platform’s features and broaden its patient support opportunities with new developments anticipated in the coming months. For more information about the RAISE platform, please reach out to the Tigerlily team at: support@tigerlilyfoundation.org.

About Tigerlily Foundation
Tigerlily Foundation is a national breast cancer foundation providing education, awareness, advocacy, and hands-on support to young women (ages 15-45) – before, during, and after breast cancer. Tigerlily programs seek to educate and empower women of all backgrounds, including those at heightened risk, those facing health disparities, and those with less access to care. Tigerlily improves the quality of life and ends isolation among breast cancer survivors. More information on the Tigerlily Foundation can be found at www.tigerlilyfoundation.org.

Media Contact:
Shanda Cooper, Tigerlily Foundation, (888) 580-6253, shanda@tigerlilyfoundation.com